Blog

Ali Taher: Phase 3 trial of Mitapivat in NTDT

Ali Taher/X

Jun 22, 2025, 02:03

Ali Taher: Phase 3 trial of Mitapivat in NTDT

Ali Taher, Director of Naef K. Basile Cancer Institute, posted on X:

“Thrilled to share that our global Phase 3 trial of mitapivat in NTDT—where I served as global PI and lead author—has been accepted in The Lancet!

A game changer: the first oral disease-modifying therapy in NTDT. Proud this was led from Lebanon.”

Title: Mitapivat in adults with non-transfusion-dependent α-thalassaemia or β-thalassaemia (ENERGIZE): a phase 3, international, randomised, double-blind, placebo-controlled trial

Authors: Ali T. Taher, Hanny Al-Samkari, Yesim Aydinok, Martin Besser, Audra N. Boscoe, Jayme L. Dahlin, Gonzalo De Luna, Jeremie H. Estepp, Sarah Gheuens, Keely S. Gilroy, Andreas Glenthøj, Ai Sim Goh, Varsha Iyer, Antonis Kattamis, Sandra R. Loggetto, Susan Morris, Khaled M. Musallam, Kareem Osman, Paolo Ricchi, Eduardo Salido-Fiérrez, Stefanie Sacknoff

Read The Full Article at The Lancet.

Ali Taher: Phase 3 trial of Mitapivat in NTDT

M	T	W	T	F	S	S
	1	2	3	4	5	6
7	8	9	10	11	12	13
14	15	16	17	18	19	20
21	22	23	24	25	26	27
28	29	30	31

Blog

OncoDaily

Blog

Ali Taher: Phase 3 trial of Mitapivat in NTDT

“Thrilled to share that our global Phase 3 trial of mitapivat in NTDT—where I served as global PI and lead author—has been accepted in The Lancet!

A game changer: the first oral disease-modifying therapy in NTDT. Proud this was led from Lebanon.”